Procalcitonin-Guided Sepsis Management

Role of PCT in Sepsis Diagnosis and Management

The Society of Critical Care Medicine recommends Procalcitonin (PCT) as a supportive biomarker for guiding antibiotic discontinuation decisions in critically ill patients with new fever and no clear focus of infection, particularly in those with low to intermediate clinical probability of bacterial infection 1, 4
PCT serves as a complementary tool to clinical assessment in sepsis management, with higher diagnostic accuracy and specificity (77%) than C-reactive protein (CRP) (61%) for bacterial infections 1, 3
PCT should not be used alone to withhold antibiotics in suspected sepsis cases, but rather to guide antibiotic discontinuation once patients have stabilized 1, 2

PCT levels <0.5 μg/L or decreases of ≥80% from peak levels can safely guide antibiotic discontinuation in stabilized ICU patients 1
The Stop Antibiotics on Procalcitonin Guidance Study demonstrated both reduced antibiotic exposure and improved mortality in critically ill patients using PCT-guided therapy 1
A meta-analysis of 11 randomized controlled trials involving 4,482 patients showed that PCT-guided antibiotic treatment in ICU patients with infection resulted in improved survival and shorter antibiotic treatment duration 1, 3

PCT should always be correlated with clinical judgment and not used as the sole decision-making tool 1, 5
Most PCT trials excluded severely immunocompromised patients, limiting generalizability to this population 1

Serial measurements of PCT are more valuable than single determinations for monitoring treatment response 4
PCT testing should be combined with other clinical and laboratory parameters for optimal decision-making in sepsis management 1, 4